Company profile

Cytel

Clinical Trials & Research

Company profile

About Cytel

Cytel is a global clinical research organization that delivers advanced analytics, data science, and software solutions to pharmaceutical and biotechnology companies throughout the drug development lifecycle. The company specializes in innovative trial design methodologies including adaptive trial designs, Bayesian approaches, and model-informed drug development. Cytel's comprehensive service portfolio spans discovery and preclinical research, Phase I-III clinical trials, commercialization strategies, and real-world evidence generation. The organization offers strategic consulting, functional service provider models, and project-based analytical solutions tailored to client needs. Cytel's proprietary software platforms include East Horizon for trial design, the Xact software suite (including StatXact), Enforesys for trial implementation, and LiveSLR for systematic literature reviews. The company serves diverse therapeutic areas with particular expertise in rare diseases, oncology, and central nervous system disorders. Cytel provides specialized capabilities in health economics and outcomes research (HEOR), market access strategy, regulatory compliance, data monitoring committees, and real-world data analytics. Their solutions integrate advanced statistical methods with regulatory expertise to optimize trial efficiency, enhance probability of success, and accelerate time to market for new therapeutics.

Company description Cytel official website

Primary marketClinical Trials & Research
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Cytel?

Claim this profile to manage Company information and connect with the Health AI Central audience.

Claim this listing

01 · Operating footprint

Where the Company operates

Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.

Clinical focus

  • Central Nervous System disorders
  • Oncology
  • Pediatrics
  • Rare Diseases

Who it serves

  • Biotech
  • Pharma

Deployment & integration

Cloud Saas · On Premise deployment with recorded integration context.

Geographic context

MarketsGlobal
Company sourceOfficial website

Company milestones

Platform expansion

Company milestone context is currently being developed.

Partnerships

Recorded partners

  • stève consultants

02 · Flagship portfolio

Products, workflows, and platform capabilities

Selected source-backed Company products and the available commercial context.

Axio Data Monitoring Committee

Data monitoring and safety oversight platform for clinical trials

Platform · Cloud SaaSCompany source

East Horizon

Platform for clinical trial design and simulation

Platform · Cloud SaaSCompany source

Enforesys

Trial implementation and decision support software

Software · Cloud SaaSCompany source

LiveSLR

Software for systematic literature reviews in clinical research

Software · Cloud SaaSCompany source

Xact Software Suite (StatXact)

Statistical software for clinical trial analysis

Software · On PremiseCompany source

03 · Research intelligence

Research Intelligence evidence

Publications, preprints, clinical validation, and regulatory records in Evidence Position order.

Evidence position

Publications, clinical validation, and regulatory records connected to this Company appear here.

Research

Publications & preprints

Estimating clinical and economic impacts and cost-effectiveness of introducing 20-valent pneumococcal conjugate vaccine in Taiwan's pediatric National Immunization Program and impacts of a delayed implementation.

Human vaccines & immunotherapeutics · Dec 1, 2026

Incidence of New Malignancies in Severe Asthma: Comparison of Real-World Patients Treated with Benralizumab, Other Biologics, or Non-biologics.

Pulmonary therapy · Aug 28, 2026

A health-economic assessment of the impact of different RSVpreF maternal vaccine strategies to prevent RSV infections among young infants, in France: EPIPACT.

Vaccine · Aug 21, 2026

Risk factors and cognitive domain markers of progression in subjective cognitive decline.

Journal of Alzheimer's disease : JAD · Aug 12, 2026

A real-world study on hospital and economic burden of dengue fever in French overseas territories.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · Jul 25, 2026

A Matching-Adjusted Indirect Comparison of PET-Guided BrECADD Versus PET-Guided ABVD, BEACOPP, and eBEACOPP in Advanced Hodgkin Lymphoma.

Advances in therapy · Jul 23, 2026

Clinical validation

Clinical-trial records

The PhINEST Study - Pharyngeal ICU Novel Electrical Stimulation Therapy

NCT03840395 · Sponsor · TERMINATED

Videofluoroscopic Swallowing Study (VFSS)

NCT03387267 · Sponsor · TERMINATED

Pharyngeal Electrical Stimulation Evaluation for Dysphagia After Stroke

NCT03358810 · Sponsor · COMPLETED

Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms

NCT04727424 · Sponsor · UNKNOWN

Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.

NCT04731298 · Sponsor · TERMINATED

A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant

NCT04494061 · Sponsor · TERMINATED

Regulatory

Regulatory records

No linked records are currently available.

04 · Company-reported outcomes

Outcomes and case studies

Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.

No Company-reported outcomes are currently listed.

05 · Leadership

Leadership team

Leadership profiles and professional links from the current Company record.

No active leadership profiles are currently listed.

06 · Company updates

Updates from Cytel

Recent articles published on Cytel's official website.

No Company updates are currently listed.

07 · HAIC coverage

Coverage and analysis

Health AI Central reporting that mentions this Company.

No HAIC coverage is currently linked to this Company.

08 · Official presence

Company sources and channels

Curated official destinations from the active Company record.

09 · Market pathway

Additional Companies in this Market

Other active Companies in the same market, selected alphabetically from the HAIC directory.

Market context

Clinical Trials & Research

Companies using AI to optimize clinical trial design, accelerate patient recruitment, match patients to trials, predict trial outcomes, or improve clinical research efficiency. Includes patient enrollment and screening platforms, AI-powered trial matching, and tools that reduce the time and cost of bringing new treatments to market.

Explore the full market directory or compare this Company with additional active profiles.

View all Companies in this market

10 · Pro research

Coming soon

Expanded Company research is in development.

Health AI Central Pro · Coming Soon

Deeper Company research is coming soon.

Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.

ResearchEvidence analysis

Linked research, clinical, and regulatory source pathways.

CompanyTechnical context

Expanded product, deployment, integration, and partnership research.

MethodSource & review record

Record-level provenance and review context.

Coming Soon